Curated News
By: NewsRamp Editorial Staff
November 06, 2026

SS Innovations' SSi Mantra Tops 15,000 Robotic Surgeries

Discuss on LinkedInDiscuss on X, formerly TwitterDiscuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • SS Innovations' SSi Mantra has enabled over 15,000 procedures and 66% revenue growth to $25 million, positioning it for global expansion.
  • The SSi Mantra platform features 4K 3D visualization, surgeon-controlled imaging, and a modular design with up to five robotic arms.
  • Telesurgery via SSi Mantra extends specialist surgical care to underserved communities, improving access to advanced procedures.
  • SS Innovations has performed over 200 telesurgeries, including 27 cardiac cases, showcasing remote robotic surgery's potential.

Impact - Why it Matters

The rapid adoption of SS Innovations’ SSi Mantra robotic surgical system signals a shift toward more accessible, affordable robotic surgery, particularly in emerging markets. With over 15,000 procedures performed and a growing telesurgery program, the company is helping to democratize specialized surgical care, potentially improving outcomes for patients in underserved regions. As SS Innovations expands manufacturing and pursues regulatory approvals in Europe and the U.S., it could intensify competition in the robotic surgery market, driving down costs and accelerating innovation. For investors, the company’s 66% year-over-year revenue growth in the first half of 2026 demonstrates strong commercial traction in a high-growth medtech sector.

Summary

SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, is gaining significant traction with its SSi Mantra surgical robotic platform, according to CEO Dr. Sudhir Srivastava in a recent interview with The Motley Fool’s Rachel Warren. Srivastava revealed that the company has performed more than 15,000 procedures using its robotic systems, including approximately 750 cardiac surgeries, and over 200 telesurgeries, of which 27 were cardiac. These milestones underscore the platform’s clinical versatility and the company’s efforts to extend specialist surgical expertise to underserved communities through telesurgery.

Srivastava highlighted the SSi Mantra’s differentiated engineering, including 4K 3D visualization, surgeon-controlled anatomical imaging, and a modular design that supports up to five robotic arms. The company is also preparing to expand its Indian manufacturing capacity with a planned 10-acre facility, aiming to bring additional production capabilities in-house. Regulatory applications in Europe and the United States are progressing, and management is targeting international expansion through direct sales and opportunities in ambulatory surgery centers. Financially, SS Innovations is experiencing strong commercial momentum, with first-half 2026 revenue increasing approximately 66% year-over-year to about $25 million.

As SS Innovations International (NASDAQ: SSII) continues to advance its robotic surgery platform, the combination of technological innovation, clinical experience, and affordability is driving adoption. The company’s growth strategy, which includes scaling manufacturing and pursuing global regulatory approvals, positions it to capitalize on the growing demand for robotic-assisted surgery. For more details, read the full interview here.

Source Statement

This curated news summary relied on content distributed by NewMediaWire. Read the original source here, SS Innovations' SSi Mantra Tops 15,000 Robotic Surgeries

Blockchain registration record for this content